Q-omics provides the consensus-scored FANCD2P2 profile across patient tissues and cancer cell-line models. FANCD2P2 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, FANCD2P2 is differentially expressed in 6, with the highest sampling consensus in LUSC. Additionally, FANCD2P2 RNA expression shows 6,304 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, LUSC, and STAD as cancer lineages where FANCD2P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FANCD2P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FANCD2P2 survival associations across molecular data types. FANCD2P2 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FANCD2P2 RNA expression–survival associations across cancer types. High FANCD2P2 expression shows unfavorable associations in MESO, ESCA, LUAD, KIRC and OV, but favorable associations in KIRP. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for FANCD2P2 RNA expression.
This table summarizes FANCD2P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for FANCD2P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FANCD2P2 shows higher tumor expression in LUSC, LIHC, UCEC, BLCA, LUAD and HNSC. The LUSC box plot shows higher FANCD2P2 RNA expression in tumor versus normal tissue (log2 FC = +0.150, t-test p = .001).
This table shows molecular features associated with FANCD2P2 in patient tissues and cancer cell lines. In patient samples, FANCD2P2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, FANCD2P2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN.
